Filing Flows › Supernus Pharmaceuticals (SUPN) › Q2 2026 › vs Q1 2026
Supernus Pharmaceuticals (SUPN) Q2 2026 vs Q1 2026 (quarter over quarter)
Supernus Pharmaceuticals's revenue rose $11.4M (+5%) from $208M in Q1 2026 to $219M in Q2 2026. The biggest changes: Net product sales +$6.7M (+4%); ONAPGO +$5.2M (+62%); Other −$2.8M (-60%).
Supernus Pharmaceuticals, Q2 2026: revenue $219M (+32% year over year), operating margin -26.5%, net loss $58.4M, operating cash flow −$4.8M. The chart draws each line against Q1 2026, the increases inside each band.
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Qelbree | $89.2M | $77.8M | $11.4M | +15% |
| Collaboration revenue (ZURZUVAE) | $35.4M | $27.6M | $7.7M | +28% |
| Royalty, licensing, and other revenues | $18.0M | $29.3M | −$11.3M | -39% |
| Oxtellar XR | $8.8M | $7.4M | $1.4M | +18% |
| Trokendi XR | $8.4M | $9.5M | −$1.1M | -11% |
| APOKYN | $6.3M | $7.7M | −$1.4M | -18% |
| Net product sales | $166M | $159M | $6.7M | +4% |
| GOCOVRI | $37.5M | $35.2M | $2.3M | +6% |
| ONAPGO | $13.5M | $8.4M | $5.2M | +62% |
| Other | $1.9M | $4.7M | −$2.8M | -60% |
| Revenue | $219M | $208M | $11.4M | +5% |
| Net loss | $58.4M | $2.3M | $56.1M | 25× |
| Costs & expenses | $278M | $216M | $61.7M | +29% |
| Operating costs | $277M | $216M | $61.0M | +28% |
| Income tax | $723K | −$3.7M | $4.4M | — |
| Cost of revenue | $33.7M | $23.4M | $10.3M | +44% |
| Research & development | $29.5M | $39.4M | −$10.0M | -25% |
| SG&A | $134M | $125M | $8.5M | +7% |
| Other operating costs | $80.3M | $28.0M | $52.2M | +186% |
| Operating cash sources | $58.4M | $2.3M | $56.1M | 25× |
| Depreciation & amortization | $25.7M | $26.1M | −$385K | -1% |
| Share-based compensation | $8.6M | $8.5M | $160K | +2% |
| Working capital & other | $19.2M | $34.2M | −$15.0M | -44% |
| Cash used in operations | $4.8M | −$66.5M | $71.3M | — |
| Net loss absorbed | $58.4M | $2.3M | $56.1M | 25× |
Questions
How much did Supernus Pharmaceuticals's revenue grow quarter over quarter in Q2 2026?
Supernus Pharmaceuticals's revenue rose $11.4M (+5%) from $208M in Q1 2026 to $219M in Q2 2026.
What drove Supernus Pharmaceuticals's revenue change in Q2 2026?
Net product sales +$6.7M (+4%); ONAPGO +$5.2M (+62%); Other −$2.8M (-60%).